Telplus Tablets (Telmisartan + Cilnidipine )

• Composition :
  Each tablet contains Telmisartan IP 40 mg +Cilnidipine 10 mg.
• Indications :
  Treatment of hypertension
• Pharmacodynamics :
  Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Telmisartan has much greater affinity for the AT1 receptor than for the AT2 receptor. Cilnidipine is a dihydropyridine calcium-channel blocker. It inhibits cellular influx of calcium, thus causing vasodilatation. It has greater selectivity for vascular smooth muscle
• Dosage and administration :
  One tablet once daily.
• Contraindications :
  Telplus is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) Telplus or any other component of this product and should not be prescribed in: Cardiogenic shock, Recent MI or acute unstable angina and Severe aortic stenosis.
• Precautions and warnings :
  Telmisartan- Hyperkalemia, Symptomatic hypotension, Impaired Hepatic Function, Impaired Renal Function.Cilnidipine- Hypotension, poor cardiac reserve, heart failure. Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain following administration.
• Use in pregnancy, lactation & pediatrics :
  Teratogenic Effects, Pregnancy Categories C (first trimester) and D (second and third trimesters).Discontinue the tablet as soon aspregnancy is detected, there are no adequate and well-controlled studies established for safety and efficacy in lactation and children
• Drug interactions :
  Telmisartan- Monitoring of the serum digoxin and Lithium is recommended, its effect may be attenuated by NSAIDs including selective COX-2 inhibitor, concomitant use with ACE inhibitor is not recommended.Cilnidipine can interact with aldesleukin, quinidine, phenytoin, rifampicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drugs.
• Adverse reactions :
  Telmisartan- The most common adverse events reported in hypertension trials are back pain, sinusitis, and diarrhoeaCilnidipine- Dizziness, Flushing, Headache, Hypotension, Peripheral oedema, Tachycardia, Palpitations, GI disturbances, Increased micturition frequency, Lethargy. .
• Therapy Area :
  Anti-Hypertensives